Health research in Papua New Guinea

Trends in Parasitology

Volumn 19, Issue 6, 2003, Pages 241-245

  Reeder, John C ^a  

^a PAPUA NEW GUINEA INSTITUTE OF MEDICAL RESEARCH   (Papua New Guinea)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIPROTOZOAL AGENT; APICAL MEMBRANE ANTIGEN 1; HAEMOPHILUS INFLUENZAE TYPE B VACCINE; MALARIA VACCINE; MEASLES VACCINE; MEROZOITE SURFACE PROTEIN 1; MEROZOITE SURFACE PROTEIN 2; RING INFECTED ERYTHROCYTE SURFACE ANTIGEN; UNCLASSIFIED DRUG;

ANOPHELES; CLINICAL TRIAL; COMMUNITY; COMMUNITY CARE; COST EFFECTIVENESS ANALYSIS; DEVELOPING COUNTRY; DIAGNOSTIC VALUE; DISEASE CARRIER; DRUG COST; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; ENDEMIC DISEASE; EPIDEMIOLOGICAL DATA; FILARIASIS; GENOTYPE; HEALTH CARE POLICY; HUMAN; IMMUNE RESPONSE; INCIDENCE; INFECTION CONTROL; INFECTION RISK; MALARIA; MEASLES; MEASLES VACCINATION; MEDICAL RESEARCH; MICROFILARIASIS; MODEL; MOLECULAR GENETICS; MOSQUITO; PAPUA NEW GUINEA; PARASITE TRANSMISSION; PLASMODIUM FALCIPARUM; PLASMODIUM MALARIAE; PLASMODIUM OVALE; PLASMODIUM VIVAX; PUBLIC HEALTH SERVICE; REVIEW; WUCHERERIA BANCROFTI;

HAEMOPHILUS; HAEMOPHILUS INFLUENZAE; HAEMOPHILUS INFLUENZAE SEROTYPE B; PLASMODIUM FALCIPARUM; PLASMODIUM MALARIAE; PLASMODIUM OVALE; PLASMODIUM VIVAX; PROTOZOA; WUCHERERIA; WUCHERERIA BANCROFTI;

EID: 0038016736     PISSN: 14714922     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1471-4922(03)00089-8     Document Type: Editorial

References (38)

1. Genton B., et al. A recombinant blood-stage malaria vaccine reduces Plasmodium falciparum density and exerts selective pressure on parasite populations in a phase 1-2b trial in Papua New Guinea. J. Infect. Dis. 185:2002;820-827.
2. Lawrence G. Pigbel. Attenborough R.D., Alpers M.P. Human Biology in Papua New Guinea: The Small Cosmos. 1992;335-344 Clarendon Press.
3. Alpers M.P. Kuru. Attenborough R.D., Alpers M.P. Human Biology in Papua New Guinea: The Small Cosmos. 1992;313-334 Clarendon Press.
4. Cattani J.A. The epidemiology of malaria in Papua New Guinea. Attenborough R.D., Alpers M.P. Human Biology in Papua New Guinea: The Small Cosmos. 1992;302-312 Clarendon Press.
5. Cattani J.A., et al. The epidemiology of malaria in a population surrounding Madang, Papua New Guinea. Am. J. Trop. Med. Hyg. 35:1986;3-15.
6. Genton B., et al. The epidemiology of malaria in the Wosera area, East Sepik Province, Papua New Guinea, in preparation for vaccine trials. I. Malariometric indices and immunity. Ann. Trop. Med. Parasitol. 89:1995;359-376.
7. Mueller, I. et al. The changing pattern of malaria epidemiology in the Highlands of Papua New Guinea. P. N. G. Med. J. (in press).
8. Van Dijk W.J.O.M., Parkinson A.D. Epidemiology of malaria in New Guinea. P. N. G. Med. J. 17:1974;17-21.
9. Burkot T.R., et al. Human malaria transmission studies in the Anopheles punctulatus complex in Papua New Guinea: sporozoite rates, inoculation rates, and sporozoite densities. Am. J. Trop. Med. Hyg. 39:1988;135-144.
10. Hii J.L., et al. Spatial and temporal variation in abundance of Anopheles (Diptera:Culicidae) in a malaria endemic area in Papua New Guinea. J. Med. Entomol. 34:1997;193-205.
11. Foley D.H., et al. Allozyme analysis reveals six species within the Anopheles punctulatus complex of mosquitoes in Papua New Guinea. Med. Vet. Entomol. 7:1993;37-48.
12. Cooper R.D., et al. Anopheline mosquitoes of the western province of Papua New Guinea. J. Am. Mosq. Control Assoc. 13:1997;5-12.
13. Cooper R.D., et al. Speciation and distribution of members of the Anopheles punctulatus (Diptera: Cuclicidae) group in Papua New Guinea. J. Med. Entomol. 39:2002;16-27.
14. Serjeantson S.W., et al. Population genetics in Papua New Guinea: A perspective on human evolution. Attenborough R.D., Alpers M.P., et al. Human Biology in Papua New Guinea: The Small Cosmos. 1992;Clarendon Press.
15. Genton B., et al. Ovalocytosis and cerebral malaria. Nature. 378:1995;564-565.
16. Allen S.J., et al. Alpha+-thalassemia protects children against disease caused by other infections as well as malaria. Proc. Natl. Acad. Sci. U. S. A. 94:1997;14736-14741.
17. * A(null) in a Plasmodium vivax-endemic region of Papua New Guinea. Proc. Nat. Acad. Sci. U. S. A. 96:1999;13973-13977.
18. Brown G.V., Reeder J.C. Malaria vaccines. Med. J. Aust. 177:2002;230-231.
19. Genton B., et al. The epidemiology of malaria in the Wosera area, East Sepik province, Papua New Guinea, in preparation for vaccine trials. II. Mortality and morbidity. Ann. Trop. Med. Parasitol. 89:1995;377-390.
20. Reeder J.C. Towards a malaria vaccine for Papua New Guinea. P. N. G. Med. J. 44:2001;17-23.
21. Genton B., et al. Safety and immunogenicity of a three component blood-stage vaccine in adults living in an endemic area in Papua New Guinea. Vaccine. 18:2000;2504-2511.
22. Felger I., et al. Plasmodium falciparum: extensive polymorphism in merozoite surface antigen 2 alleles in an area with endemic malaria in Papua New Guinea. Exp. Parasitol. 79:1994;106-116.
23. Felger I., et al. Sequence diversity and molecular evolution of the merozoite surface antigen 2 of Plasmodium falciparum. J. Mol. Evol. 45:1997;154-160.
24. Engelbrecht F., et al. Plasmodium falciparum: malaria morbidity associated with specific merozoite surface antigen 2 genotypes. Exp. Parasitol. 81:1995;90-96.
25. Al-Yaman F., et al. Human cerebral malaria: lack of significant association between erythrocyte rosetting and disease severity. Trans. R. Soc. Trop. Med. Hyg. 89:1995;55-58.
26. Al-Yaman F., et al. Reduced risk of clinical malaria in children infected with multiple clones of Plasmodium falciparum in a highly endemic area: a prospective community study. Trans. R. Soc. Trop. Med. Hyg. 91:1997;602-605.
27. Bruce M.C., et al. Cross-species interactions between malaria parasites in humans. Science. 287:2000;845-848.
28. Mehlotra R.K., et al. Evolution of a unique Plasmodium falciparum chloroquine-resistance phenotype in association with pfcrt polymorphism in Papua New Guinea and South America. Proc. Natl. Acad. Sci. U. S. A. 98:2001;12689-12694.
29. Cole-Tobian J., et al. Age-acquired immunity to a plasmodium vivax invasion ligand, the Duffy binding protein. J. Infect. Dis. 186:2002;531-539.
30. Michael E., Bundy D.A.P. Global mapping of lymphatic filariasis. Parasitol. Today. 13:1997;472-476.
31. Alexander N.D., et al. Acute episodes in a Wuchereria bancrofti-endemic area of Papua New Guinea. Am. J. Trop. Med. Hyg. 61:1999;319-324.
32. Bockarie M.J., et al. Randomised community-based trial of annual single-dose diethylcarbamizine with or without ivermectin against Wuchereria bancrofti infections in human beings and mosquitoes. Lancet. 351:1998;162-168.
33. Kazura J.W., et al. Transmission intensity and its relationship to infection and disease due to Wuchereria bancrofti in Papua New Guinea. J. Infect. Dis. 176:1997;242-246.
34. King C.L., et al. Transmission intensity determines lymphocyte responsiveness and cytokine bias in human lymphocytic filariasis. J. Immunol. 166:2001;7427-7436.
35. Tisch D.J., et al. Ecological and biological determinants of filarial antigenemia in bancroftian filariasis in Papua New Guinea. J. Infect. Dis. 184:2001;898-904.
36. Bockarie M.J., et al. Transmission dynamics of Wuchereria bancrofti in East Sepik Province Papua New Guinea. Am. J. Trop. Med. Hyg. 54:1996;577-581.
37. Bockarie M.J., et al. Mass treatment to eliminate filariasis in Papua New Guinea. N. Engl. J. Med. 347:2002;1841-1848.
38. Ottensen E.A. Major progress towards eliminating lymphatic filariasis. N. Engl. J. Med. 347:2002;1885-1886.